ΠΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΡΠ°ΡΡΡΠ° Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠ°ΡΡΠΎΠΉ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠΎΠ²ΠΎΠΉ ΡΠΊΡΡΡΠ°ΡΠΈΡΡΠΎΠ»ΠΈΠ΅ΠΉ Π±Π΅Π· ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² ΠΎΡΠ³Π°Π½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ
ΠΠΈΡΡΠ΅ΡΡΠ°ΡΠΈΡ
ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΡΡ Π°ΡΠΈΡΠΌΠΈΠΉ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΠ΄Π½ΠΎΠΉ ΠΈΠ· Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌ Π² ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Π΅. ΠΠ°ΡΡΡΠ΅Π½ΠΈΡ ΡΠΈΡΠΌΠ° ΡΠ΅ΡΠ΄ΡΠ° (ΠΠ Π‘) Π½Π΅ΡΠ΅Π΄ΠΊΠΎ ΠΎΡΠ»ΠΎΠΆΠ½ΡΡΡ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΡΠ΅ΡΠ΄ΡΠ°, ΡΠ°ΠΊΠΈΡ ΠΊΠ°ΠΊ ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠ°Ρ Π±ΠΎΠ»Π΅Π·Π½Ρ ΡΠ΅ΡΠ΄ΡΠ° (ΠΠΠ‘), Π΄ΠΈΠ»Π°ΡΠ°ΡΠΈΠΎΠ½Π½Π°Ρ ΠΊΠ°ΡΠ΄ΠΈΠΎΠΌΠΈΠΎΠΏΠ°ΡΠΈΡ (ΠΠΠΠ), ΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΡ, Π³ΠΈΠΏΠ΅ΡΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ Π±ΠΎΠ»Π΅Π·Π½Ρ (ΠΠ) ΠΈ Π΄ΡΡΠ³ΠΈΠ΅. Π‘ΡΠ΅Π΄ΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ ΠΏΠ°ΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΡΠ°Π·Π²ΠΈΡΠΈΡ Π°ΡΠΈΡΠΌΠΈΠΈ… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- Zheng Z, Croft J, Giles W, Mensah G. Sudden cardiac death in the United States, 1989 to 1998/Z. Zheng// Circulation-2001. vol. 104-p. 2158−2163.
- Shah M, Akar FG, Tomaselli GF. Molecular basis of arrhythmias /Π. Shah// Circulation-2005.-vol. 112.-p. 2517−2529.
- ΠΡΡΠ°ΠΊΠΎΠ²ΡΠΊΠΈΠΉΠ.Π‘. «ΠΡΠΈΡΠΌΠΈΠΈ ΡΠ΅ΡΠ΄ΡΠ°». Π ΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²ΠΎ Π΄Π»Ρ Π²ΡΠ°ΡΠ΅ΠΉ. 1998 Π‘Π°Π½ΠΊΡ-ΠΠ΅ΡΠ΅ΡΠ±ΡΡΠ³: «Π€ΠΎΠ»ΠΈΠ°Π½Ρ».
- Lazzerini Π Π, Capecchi PL, Guideri F et al. Connective tissue diseases and cardiac rhythm disorders: an overview /Π Π. Lazzerini// Autoimmun Rev-2006. -vol. 5.-p. 306−313.
- ΠΠΎΠ΄ ΡΠ΅Π΄. E. Π. Π§Π°Π·ΠΎΠ²Π°, Π‘. Π. ΠΠΎΠ»ΠΈΡΡΠ½Π°. Π ΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²ΠΎ ΠΏΠΎ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΡΠΈΡΠΌΠ° ΡΠ΅ΡΠ΄ΡΠ°-Π: ΠΠΠΠ’ΠΠ -ΠΠ΅Π΄ΠΈΠ° 2008- 416Ρ.
- ΠΠ΅ΠΊΠ±ΠΎΡΡΠΏΠΎΠ²Π° Π.Π‘., Π₯Π°ΡΡΠΈΠ½ Π. Π., ΠΡΠΊΠΎΡΠΊΠΎΠ²Π° Π. Π., ΠΠΎΠ»ΠΈΡΡΠ½ Π‘. Π. Π‘ΠΏΠ΅ΠΊΡΡΠ°Π»ΡΠ½ΡΠ΅ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈ ΠΊΠΎΠ»Π΅Π±Π°Π½ΠΈΠΉ Π§Π‘Π‘ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΡΠΏΡΠ°Π²Π΅Π½ΡΡΠΈΠΊΡΠ»ΡΡΠ½ΡΠΌΠΈ ΠΈ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠΎΠ²ΡΠΌΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ ΡΠΈΡΠΌΠ° ΡΠ΅ΡΠ΄ΡΠ° Π½Π° ΡΠΎΠ½Π΅ ΠΏΡΠΈΠ΅ΠΌΠ° Ρ ΠΈΠ½ΠΈΠ΄ΠΈΠΏΠ° /Π.Π‘. ΠΠ΅ΠΊΠ±ΠΎΡΡΠΏΠΎΠ²Π°// ΠΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ-1997.
- ΠΠ°Π·ΡΠ³ΡΠ»Π° Π.Π. ΠΠ°ΡΠΈΠ°Π±Π΅Π»ΡΠ½ΠΎΡΡΡ ΡΠΈΡΠΌΠ° ΡΠ΅ΡΠ΄ΡΠ° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡΠΌΠΈ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠΎΠ²ΠΎΠΉ ΡΠΊΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ, Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° Π½Π΅Π΅ Π°Π½ΡΠΈΠ°ΡΠΈΡΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΠΈΡΡ. ΠΊΠ°Π½Π΄. ΠΠ΅Π΄. ΠΠ°ΡΠΊ. ΠΠΎΡΠΊΠ²Π°, 2001.
- ΠΠ°Π·ΡΠ³ΡΠ»Π° Π.Π., ΠΡΠΊΠΎΡΠΊΠΎΠ²Π° Π. Π., ΠΠΎΠ»ΠΈΡΡΠ½ Π‘. Π. Π‘ΠΏΠ΅ΠΊΡΡΠ°Π»ΡΠ½ΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π²Π°ΡΠΈΠ°Π±Π΅Π»ΡΠ½ΠΎΡΡΠΈ ΡΠΈΡΠΌΠ° ΡΠ΅ΡΠ΄ΡΠ° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡΠΌΠΈ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠΎΠ²ΠΎΠΉ ΡΠΊΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ /Π.Π. ΠΠ°Π·ΡΠ³ΡΠ»Π°// ΠΡΠ°ΠΊΡΠΈΠΊΡΡΡΠΈΠΉ Π²ΡΠ°Ρ-2001.-№ 20-Ρ. 2−4.
- Chiale PA, Ferrari I, Mahler E et al. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular121arrhythmias and sinus node dysfunction /Π Π Chiale// Circulation- 2001.-vol. 103(13).-p. 1765−1771.
- Chiale PA, Rosenbaum MB, Elizari MV et al. High prevalence of antibodies against beta 1- and beta 2-adrenoceptors in patients with primary electrical cardiac abnormalities /Π Π Chiale// J Am Coll Cardiol-1995.- vol. 26(4).- p. 864−869.
- Π¨Π»ΡΡ ΡΠΎ E.B., Π’ΡΠ΅ΡΠΊΡΡ T.B., ΠΠ°ΡΠΌΠΎΠ½ E.B. ΠΈ Π΄Ρ. ΠΠ΄ΠΈΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΡΠΈΡΠΌΠ°: ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ/ Π.Π. Π¨Π»ΡΡ ΡΠΎ// ΠΠ΅ΡΡΠ½ΠΈΠΊ Π°ΡΠΈΡΠΌΠΎΠ»ΠΎΠ³ΠΈΠΈ -2003.-β ΠΠ.-Ρ. 5−11.
- Bigger JT. Identification of patients at high risk for sudden cardiac death /Bigger JT// Am -1984.-vol. 54(9). p. 3D-8D.
- Buxton AE, Waxman HL, Marchlinski FE et al. Right ventricular tachycardia: clinical and electrophysiologic characteristics / AE Buxton// Circulation- 1983. -vol. 68(5).-p. 917−927.
- Bikkina M, Larson MG, Levy D. Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham Heart Study / M. Bikkina// Ann Intern Med- 1992.- vol.117(12).- p. 990−996.
- Lecomte D., Fornes P. at al. Isolated myocardial fibrosis as a couse of sudden cardiac death and possible relation to myocarditis /D. Lecomte// J Forensic Sci.- 1993.- vol. 38.-p. 617−621.
- Kawai C. Idiopathic cardiomyopathy: a study on the infectious-immune theory as a cause of the disease /Π‘. Kawai// Jpn Circ J-1971. vol. 35.- p. 765−770.
- Kawai C, Matsumori A, Kitaura Y, Talcatsu T. Viruses and the heart: viral myocarditis and cardiomyopathy/C. Kawai// Prog Cardiol- 1978.- vol. 7.- p. 141−162.
- Calabrese F, Thiene G. Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects /F.Calabrese// Cardiovasc Res- 2003. vol. 60(1).- p. 11−25.
- Aretz HT. Myocarditis: the Dallas criteria IRT AretzII Hum Pathol- 1987. -vol. 18.-p. 619−624.
- Hufnagel G, Pankuweit S, Richter A et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results /G. Hufnagel // Herz 2000. — vol. 25(3).- p. 279 285.
- Martin AB, Webber S, Fricker FJ et al. Acute myocarditis. Rapid diagnosis by PCR in children /AB Martin// Circulation 1994- vol. 90(1). — p. 330−339.
- Moimas S, Zacchigna S, Merlo M et al. Idiopathic dilated cardiomyopathy and persistent viral infection: Lack of association in a controlled study using a quantitative assay /S. Moimas// Heart Lung Circ- 2012. vol. 21(12). — p. 787 793.
- Takano H, Nakagawa K, Ishio N et al. Active myocarditis in a patient with chronic active Epstein-Barr virus infection /H. Takano // Int J Cardiol 2008.-vol 130(1).-p.l 1−13.
- Woodruff JF. Viral myocarditis / JF Woodruff// Am J Pathol 1980. — vol. 101 (2).-p. 425−484.
- Francalanci P, Chance JL, Vatta M et al. Cardiotropic viruses in the myocardium of children with end-stage heart disease /P. Francalanci// J Heart Lung Transplant- 2004.- vol. 23(9).- p. 1046−1105
- Savon C, Acosta B, Valdes O et al. A myocarditis outbreak with fatal cases associated with adenovirus subgenera C among children from Havana City in 2005 /C. Savon// J ClinVirol 2008.- vol. 43(2).- p. 152−157
- Dennert R, Crijns HJ, I-Ieymans S. Acute viral myocarditis /R. Dennert// Eur Heart J.- 2008.- vol. 29, — p 2073−2082.
- Bachmaier K, Neu N, de la Maza LM et al. Chlamydia infections and heart disease linked through antigenic mimicry /K. Bachmaier // Science- 1999.-vol. 283(5406).-p. 1335−1339.
- Odeh M, Oliven A. Chlamydial infections of the heart /M. Odeh// Eur J Clin Microbiol Infect Dis- 1992.-vol. 11.- p. 885−893.
- Kyto V, Vuorinen T, Saukko P et al. Cytomegalovirus infection of the heart is common in patients with fatal myocarditis/V. Kyto// Clin Infect Dis- 2005. -vol. 40(5).- p. 683−8.
- Wreghitt T, Cary N. Virus infections in heart transplant recipients and evidence for involvement of the heart. In: Banatvala JE, editor, Viral infections of the heart, London: Hodder and Stoughton- 1993. p. 240−250.
- Maisch B, Schonian U, Crombach M et al. Cytomegalovirus associated inflammatory heart muscle disease /B. Maisch// Scand J Infect Dis 1993.-vol. 88.-p. 135−148.
- Molina KM, Garcia X, Denfield SW et al. Parvovirus B19 myocarditis causes significant morbidity and mortality in children /KM Molina// Pediatr Cardiol-2013.- vol. 34(2).-p. 390−397.
- Hall CJ. Parvovirus B19 infection in pregnancy /CJ Hall //Arch Dis Child Fetal Neonatal Ed- 1994.- vol.71.- p. F4−5.
- Young NS. Parvovirus. In: Fields BN, Knipe DM, Howley PM editors, Virology, Philadelphia: Lippincot-Raven- 1996.- p. 2199−2220.
- Porter HJ, Quantrill AM, Fleming KA. B19 parvovirus infection of myocardial cells /HJ Porter // Lancet -1988.-vol. 1.- p. 535−536.
- Gerzen P, Granath A, Holmgren B, Zetterquist S. Acute myocarditis. A follow-up study /P. Gerzen // Br Heart J- 1972.-vol. 34.- p. 575−583.
- Cambridge G, MacArthur CG, Waterson AP et al. Antibodies to Coxsackie B viruses in congestive cardiomyopathy /G. Cambridge // Br Pleart J- 1979.- vol. 41.-p. 692−696.
- Yang YZ, Jin PY, Guo Q, Wu WZ et al. Treatment of experimental Coxsackie B-3 viral myocarditis with Astragalus membranaceus in mice /YZ Yang// Chin Med J (Engl) — 1990.- vol. 103(l).-p. 14−18.
- ΠΠΎΠ²ΠΈΠΊΠΎΠ²Π° Π.Π‘., ΠΠ΅ΠΊΠ±ΠΎΡΡΠ½ΠΎΠ²Π° Π. Π‘., ΠΠΎΠ»ΠΈΡΡΠ½ Π‘. Π. ΠΈ ΡΠΎΠ°Π²Ρ. Π‘ -ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΡΠΉ Π±Π΅Π»ΠΎΠΊ ΠΈ ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½-6 Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠΎΠ²ΡΠΌΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ ΡΠΈΡΠΌΠ° ΡΠ΅ΡΠ΄ΡΠ°: Π²ΠΎΠ·ΠΌΠΎΠΆΠ½Π°Ρ ΡΠΎΠ»Ρ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠΎΠ²ΡΡ Π°ΡΠΈΡΠΌΠΈΠΉ /Π.Π‘. ΠΠΎΠ²ΠΈΠΊΠΎΠ²Π° // ΠΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ-2004.- № 5.- Ρ. 63−66.
- Gabay Π‘., Kushnewr I. Acute-phase proteins and other systemic responses to inflammation/Π‘. Gabay//N Engl J Med-1999.-340(6).- p. 448−454.
- Liuzzo G, Rizzello V. C-reactive protein and primary prevention of ischemic heart disease / G Liuzzo// Clin Chim Acta- 2001.- vol. 31 l (l).-p. 45−8.
- Π ΠΎΠΉΡ Π., ΠΡΠΎΡΡΠΎΡΡ ΠΠΆ., ΠΠ΅ΠΉΠ» Π. ΠΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡ. ΠΠ΅Ρ. Ρ Π°Π½Π³Π». Π.: ΠΠΈΡ, 2011−592 Π΅., ΠΈΠ».
- Biasucci LM, Liuzzo G, Colizzi Π‘, Rizzello V. Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease /LM Biasucci// Ital Heart J- 2001.- vol. 2(3).-p. 164−71.
- Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M et al. C-reactive protein as a predictor of improvement and readmission in heart failure /Alonso-Martinez JL// Eur J Heart Fail- 2002.- vol. 4(3).- p. 331−336.
- Choi EY, Yan RT, Fernandes VR et al. Iligh-sensitivity C-reactive protein as an independent predictor of progressive myocardial functional deterioration: the multiethnic study of atherosclerosis /EY Choi// Am Heart J- 2012.- vol. 164(2).- p. 251−258.
- Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men /PM Ridker// N Eng J Med- 1997,-vol. 336.-p. 973−979.
- Samuel Adamsson, Eryd J. Gustav Smith, Olle Melander, Bo Hedblad. Inflammation-sensitive proteins and risk of atrial fibrillation: a population-based cohort study /Samuel Adamsson// Eur J Epidemiol -2011.- vol. 26.-p. 449455.
- Mihm MJ, Yu F, Carnes CA, Reiser PJ et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. /MJ Mihm// Circulation-2001. vol. 104(2).-p. 174−180.
- Ryden L. In: Lontie R, editor. Copper proteins and copper enzymes. Boca Raton, Florida: CRC Press- 1984.- p. 37−100.
- Ozaydin M, Peker O, Erdogan D et al. N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study /M. Ozaydin// Eur Heart J.-2008.- vol. 29(5).- p. 625−631.
- Neuman RB, Bloom HL, Shukrullah I et al. Oxidative stress markers are associated with persistent atrial fibrillation /RB Neuman// Clin Chem- 2007,-vol. 53(9).-p. 1652−1657.
- Kumagai K, Khrestian C, Waldo AL. Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model. Insights into the mechanism of its maintenance /K. Kumagai// Circulation -1997.- vol. 95.-p. 511−521.
- Shimano M, Shibata R, Inden Y et al. Reactive oxidative metabolites are associated with atrial conduction disturbance in patients with atrial fibrillation M Shimano// Heart Rhythm- 2009.-vol. 6.- p. 935−940.
- Schnabel RB, Larson MG, Yamamoto JF et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation /RB Schnabel// Am J Cardiol-2009.- vol. 104(l).-p. 92−96.
- Chen MC, Chang JP, Liu WH, et al. Increased inflammatory cell infiltration in the atrial myocardium of patients with atrial fibrillation/ MC Chen // Am J Cardiol- 2008.- vol. 102.-p. 861−865.
- Nakamura Y, Nakamura K, Fukushima-Kusano K et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis IY Nakamura// Thromb Res-2003-vol. 111.-p. 137−142.
- Yamashita T, Sekiguchi A, Iwasaki YK et al. Recruitment of immune cells across atrial endocardium in human atrial fibrillation /Yamashita T// Circulation J- 2010.- vol. 74.- p. 262−270.
- Chung MK, Martin DO, Sprecher D et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation /MK Chung // Circulation- 2001 .-vol. 104.-p. 2886−2891.
- Hernandez Madrid A, Moro C. Atrial fibrillation and C-reactive protein: searching for local inflammation /Hernandez Madrid A// J Arn Coll Cardiol-2007.-vol. 49,-p. 1649−1650.
- Li J, Solus J, Chen Q, et al. Role of inflammation and oxidative stress in atrial fibrillation/J. Li//Heart Rhythm- 2010.-vol. 7.-p. 438−444.
- Psychari SN, Apostolou TS, Sinos L et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation /SN Psychari//Am J Cardiol- 2005.- vol. 95.-p. 764−767.
- Ramos-Mondragon R, Galindo CA, Avila G. Role of TGF-beta on cardiac structural and electrical remodeling /R. Ramos-Mondragon// Vase Health Risk Manag- 2008.- vol. 4.- p. 1289−1300.
- Lin CC, Lin JL, Lin CS, et al. Activation of the calcineurin-nuclear factor of activated T-cell signal transduction pathway in atrial fibrillation /CC Lin// Chest-2004.-vol. 126.-p. 1926−1932.
- Maury CP, Teppo AM. Circulating tumour necrosis factor-alpha (cachectin) in myocardial infarction /CP Maury// J Intern Med- 1989.-vol. 225(5).-p. 333 336.
- H Tilg, W Vogel, M I-Ierold, W E Aulitzky, and C Huber. Cachexia and tumour necrosis factor-alpha in cytomegalovirus infection /H. Tilg// J Clin Pathol- 1991.-vol. 44(6).-p. 519−520.
- Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure /B. Levine// N Engl J Med- 1990.-vol. 323(4).-p. 236−241.
- Gullestad L, Ueland T, Vinge LE et al. Inflammatory cytokines in heart failure: mediators and markers /L. Gullestad// Cardiology- 2012.- vol. 122(1).-p. 23−35.
- Bryant D, Becker L, Richardson Jet al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha /D. Bryant// Circulation-1998.- vol. 97(14).-p. 1375−1381.
- Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR. Role of IL-1 and tumor necrosis factor in Coxsackie virus-induced autoimmune myocarditis/JR Lane//J Immunol- 1993.- vol.51(3).- p. 1682−1690.
- Matsumori A, Sasayama S. The role of inflammatory mediators in the failing heart: immunomodulation of cytokines in experimental models of heart failure /A. Matsumori// Heart Fail Rev- 2001.- vol. 6(2).- p. 129−36.
- Matsumori A, Yamada T, Suzuki PI, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy /A Matsumori // Br Heart J-1994. vol. 72(6).- p. 561−566.
- Kurrer MO, Kopf M, Penninger JM, Eriksson U. Cytokines that regulate autoimmune myocarditis /MO Kurrer// Swiss Med Wkly- 2002.- vol. 132(29−30).-p. 408−413.
- Eriksson U, Kurrer MO, Sebald W, Brombacher F, Kopf M. Dual role of die IL-12/IFN-g axis in the development of myocarditis: induction by IL-12 and protection by IFN-g /U. Eriksson// J Immunol -2001.-vol. 167.-p. 5464−5469.
- Afanasyeva M, Wang Y, Kaya Z, Park S, Zilliox MJ, Schofield BH, Hill SL, et al. Experimental autoimmune myocarditis in A/J mice is an Interleukin-4 dependent disease with a Th2 phenotype /M. Afanasyeva// Am J Pathol-2001.-vol. 159.-p. 193−203.
- Horwitz MS, La Cava A, Fine C et al. Pancreatic expression of interferon-gamma protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis /MS Horwitz// Nat Med- 2000.- vol.6.-p. 693−697.
- Furukawa Y, Kobuke K, Matsumori A. Role of cytokines in autoimmune myocarditis and cardiomyopathy /Y. Furukawa// Autoimmunity-2001.-vol. 34(3).-p. 165−168.
- Lazzerini PE, Capecchi PL, Guideri F et al. Autoantibody-mediated cardiac arrhythmias: mechanisms and clinical implications /PE Lazzerini// Basic Res Cardiol.- 2008,-vol. 103(l).-p. 1−11.
- Bizzaro N. Autoantibodies as predictors of disease: the clinical and experimental evidence /N. Bizzaro // Autoimmun Rev 2007.- vol. 6.- p. 325 333.
- Jahns R, Boivin V, Lohse MJ. Beta 1-adrenergic receptor directed autoimmunity as a cause of dilated cardiomyopathy in rats /R. Jahns // Int J Cardiol-2006.-vol. 112, — p. 7−14.
- Nussinovitch U, Shoenfeld Y. Autoimmunity and heart diseases: pathogenesis and diagnostic criteria /U. Nussinovitch // Arch Immunol Ther Exp-2009.-vol. 57,-p. 95−104.
- Brucato A, Maestroni S, Cumetti D et al. Recurrent pericarditis: infectious or autoimmune? /A. Brucato // Autoimmun Rev-2008.-vol. 8.-p. 44−47.
- Stojanovich L, Marisavljevich D. Stress as a trigger of autoimmune disease / L Stojanovich // Autoimmun Rev 2008.-vol. 7.-p. 209−213.
- Gleicher N, Elkayam U. Peripartum cardiomyopathy, anautoimmune manifestation of allograft rejection? /N. Gleicher//Autoimmun Rev- 2009.- vol. 8.-p. 384−387.
- Zifman E, Amital H, Gilburd B, Shoenfeld Y. Antioxidantsand smoking in autoimmune disease—opposing sides of theseesaw? /E. Zifman// Autoimmun Rev-2008.- vol.8.-p. 165−169.
- Sitia S, Atzeni F, Sarzi-Puttini P et al. Cardiovascular in volvement in systemic autoimmune diseases /S. Sitia//Autoimmun Rev-2009.- vol. 8.-p. 281−286.
- Hoebeke J. Structural basis of autoimmunity against G protein-coupled membrane receptors /J. Hoebeke// Int J Cardiol-1996.-vol. 54.-p. 103−111.
- Elies R, Ferrari I, Wallukat G, et al. Structural and functional analysis of the B cell epitopes recognized by anti-receptor autoantibodies in patients with Chagas' disease/R. Elies//J Immunol 1996.-vol. 157.-p. 4203−4211.
- Ferrari I, Levin M, Wallukat G, et al. Molecular mimicry between the immunodominant ribosomal protein PO of Trypanosoma cruzi and a functional epitope on the human 01-adrenergic receptor /1. Ferrari// J Exp Med-1995.-vol. 182.-p. 59−65.
- Magnusson Y, Hjalmarson, Hoebeke J. 01-adrenoceptor autoimmunity in cardiomyopathy /Y. Magnusson// Int J Cardiol-1996.-vol. 54.-p. 137−141.
- Caforio AL, Mahon NJ, Tona F, McKenna WJ. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance /AL Caforio// Eur J Heart Fail-2002.- vol. 4.-p. 411−417.
- Rose NR. Infection, mimics, and autoimmune disease. J Clin Invest-2001.-vol. 107.-p. 943−944.
- Eriksson U, Ricci R, Hunziker L, et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity /U. Eriksson//Nat Med-2003.-vol. 9.-p. 1484−1490.
- Kennedy HL, Pescarmona JE, Bouchard RJ et al. Objective evidence of occult myocardial dysfunction in patients with frequent ventricular ectopy without clinically apparent heart disease /HL Kennedy// Am Heart J-1982.-vol. 104.-p. 5 7−65.
- Ferreiros ER, Boissonnet CP, Pizarro R et al. Independent prognostic value of elevated C-reactive protein in unstable angina /ER Ferreiros// Circulation- 1999.- vol. 100,-p. 1958−1963.
- Morrow DR, Rifai N, Antman EM et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: ATIMI 11A substudy /DR Morrow// J Am Coll Cardiol -1998.-vol. 31,-p. 1460−1465.
- Baba A, Yoshikawa T, Fukuda Y et al. Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy /A. Baba// Eur Heart J-2004.- vol. 25(13).-p. 1108−1115.
- Villecco AS, de Liberali E, Bianchi FB, Pisi E. Antibodies to cardiac conducting tissue and abnormalities of cardiac conduction in rheumatoid arthritis /AS Villecco// Clin Exp Immunol-1983.-vol. 53(3).-p. 536−540.
- Goin JC, Borda ES, Auger S et al. Cardiac M2 muscarinic cholinoceptor activation by human chagasic autoantibodies: Association with bradycardia /JC Goin// Heart-1999,-vol. 82.- p.73- 278.
- Antzelevitch C, Fish J. Electrical heterogeneity within the ventricular wall /C. Antzelevitch// Basic Res Cardiol-2001.-vol. 96.-p. 517−527.
- Medei E, Pedrosa RC, Benchimol Barbosa PR et al. Human antibodies with muscarinic activity modulate ventricular repolarization: basis for electrical disturbance /E. Medei// Int J Cardiol-2007.-vol. 115.-p. 373−380.
- Wallukat G, Nissen E, Morwinski R, Muller J. Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy /G Wallukat// Herz -2000.- vol. 25.-p. 261−266.
- Lazzerini PE, Capecchi PL, Guideri F et al. Autoantibody mediated cardiac arrhythmias: mechanisms and clinical implications /PE Lazzerini// Basic Res Cardiol-2006.-vol. 103.-p. 1−11.
- Medei E, Pedrosa RC, Benchimol Barbosa PR et al. Human antibodies with muscarinic activity modulate ventricular repolarization: basis for electrical disturbance /E Medei// Int J Cardiol-2007.-vol. 115.-p. 373−380.
- Nussinovitch N, Livneh A, Katz K et al. QT dispersion in uncomplicated familial Mediterranean fever /N Nussinovitch// Clin Rheumatol-2010.-vol. 29.-p. 1353−1356
- Nussinovitch U, Katz U, Nussinovitch M, Nussinovitch N. Late ventricular potentials and QT dispersion in familial dysautonomia /N Nussinovitch// Pediatr Cardiol -2009,-vol. 30.-p. 747−751.
- Freedman NJ, Lefkowitz RJ. Anti-hl-adrenergic receptor antibodies and heart failure: causation, not just correlation /NJ Freedman// J Clin Invest2004.-vol. 113.-p. 1379−1382.
- Frielle T, Collins S, Daniel KW, et al. Cloning of the cDNA for the human pl-adrenergic receptor /T. Frielle// Proc Natl Acad SciU S A-1987.-vol. 84.-p. 7920−7924.
- Wieland K, Zuurmond HM, Andexinger S, et al. Tereospecificity of agonist binding toh2-adrenergic receptors involves Asn-293 /K. Wieland// Proc Natl Acad Sci U S A -1996.-vol. 93.-p. 9276−9281.
- By water RP. Location and nature of theresidues important for ligand recognition in G-protein coupled receptors /RP Bywater// J Mol Recognit2005.-vol. 18.-p. 60−72.
- Dohlman ITG, Caron MG, De Blasi A, et al.:1990. Role of extracellular disulfide-bonded cysteines in the ligand binding function of the h2-adrenergic receptor/I-IG Dohlman//Biochemistry- 1990.-vol. 29.-p. 2335−2342.
- Noda K, Saad Y, Graham RM, Karnik SS. The high affinity state of the 32-adrenergic receptor requires unique interaction between conserved and nonconserved extracellular loop cysteines /K. Noda// J Biol Chem-1994.-vol. 269.-p. 6743−6752.
- Guillet JG, Hoebeke J, Lengagne R et al. Haplotype specific homology scanning algorithm to predict T cell epitopes from protein sequences /JG Guillet// J Mol Recognit-1991.-vol. 4.-p. 17−25.
- Matsui S, Fu M, Katsuda S et al. Peptides derived from cardiovascular G protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits /S. Matsui// J Mol Cell Cardiol-1997.-vol. 29.-p. 641−655.
- Jahns R, Boivin V, Krapf T et al. Modulation of h 1-adrenoceptor activity bydo main-specific antibodies and heart failure-associated autoantibodies /R. Jahns// J Am CollCardiol-2000.-vol. 36.-p. 1280−1287.
- Vilardaga JP, Steinmeyer R, Harms GS, Lohse MJ. Molecular basis of inverse agonism in a G protein-coupled receptor /JP Vilardaga// Nature Chem Biol -2005,-vol. l.-p. 25−28.
- Witebsky E, Rose NR, Terplan K et al. Chronic thyroiditis and autoimmunization/E. Witebsky//JAMA-1957.-vol. 164.-p. 1439−1447.
- Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky'spostulates revisited) /NR Rose// Immunol Today- 1993.-vol. 14.-p. 426−430.
- Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in hi-adrenergic receptor transgenic mice /S. Engelhardt // Proc Natl Acad Sei U S-1999.-vol. A96.-p. 7059−7064.
- Woodiwiss AJ, Tsotetsi OJ, Sprott S, et al. Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction /AJ Woodiwiss// Circulation-2001.-vol. 103.-p. 155−160.
- Tutor AS, Penela P, Mayor F Jr. Anti-beta 1-adrenergic receptor autoantibodies are potent stimulators of the ERK½ pathway in cardiac cells /AS Tutor// Cardiovasc Res-2007.-vol. 76.-p. 51−60.
- Hebert TE. Anti-betalAR antibodies in dilated cardiomyopathy: are these a new class of receptor agonists? /TE Hebert// Cardiovasc Res-2007.-vol. 76.-p. 5−7.
- Nussinovitch U, Katz U, Nussinovitch M et al. Echocardiographic abnormalities in familial dysautonomia /U. Nussinovitch// Pediatr Cardiol-2009.-vol. 30.-p. 1068−1074.
- Yoshikawa T, Baba A, Nagatomo Y. Autoimmune mechanisms underlying dilated cardiomyopathy /T. Yoshikawa// Circ J-2009.-vol. 73.-p. 602−607.
- Nagatomo Y, Yoshikawa T, Kohno T et al. A pilot study on the role of autoantibody targeting the beta 1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure /Y. Nagatomo// J Card Fail-2009.-vol. 15.-p. 224−232.
- Stork S, Boivin V, Plorf R et al. Stimulating autoantibodies directed against the cardiac beta 1-adrenergic receptor predict in creased mortality in idiopathic cardiomyopathy /S. Stork// Am Heart J-2006.- vol. 152.-p. 697−704.
- Medei EH, Nascimento JH, Pedrosa RC et al. Antibodies with beta-adrenergic activity from chronic chagasic patients modulate the QT interval and M cell action potential duration /EH Medei// Europace -2008.- vol. 10,-p. 868−876.
- Nussinovitch U, Shoenfeld Y. Intravenous immunoglobulin—indications and mechanisms in cardiovascular diseases /U. Nussinovitch// Autoimmun Rev-2008.-vol. 7.-p. 445152.
- Staudt Y, Mobini R, Fu M et al. Beta 1-adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes /Y. Staudt// Eur J Pharmacol-2003.-vol. 466.-p. 1−6.
- Wallukat G, Muller J, Hetzer R. Specific removal of beta 1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy /G. Wallukat// N Engl J Med-2002.-vol. 347.-p. 1806.
- Caforio AL, Tona F, Bottaro S et al. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy /AL Caforio//Autoimmunity-2008.-vol. 41.-p. 35−45
- Mobini R, Staudt A, Felix SB et al. Hemodynamic improvement and removal of autoantibodies against beta 1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy /R. Mobini// J Autoimmun -2003.-vol. 20.-p. 345−350.
- Jane-wit D, Altuntas CZ, Johnson JM et al (2007) Beta 1-adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis /D. Jane-wit// Circulation-2007.-vol. 116.-p. 399−410.
- Muller J, Wallukat G, Dandel M et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy /J. Muller// Circulation-2000.-vol. 101.-p. 385−391.
- Gao Y, Liu FIR, Zhao RR, Zhi JM. Autoantibody against cardiac betal-adrenoceptor induces apoptosis in cultured neonatal rat cardiomyocytes /Y. Gao// Acta Biochim Biophys Sin 2006.-vol. 38.- p. 443−449.
- Nussinovitch U, Shoenfeld Y. Autoimmunity and heart diseases: pathogenesis and diagnostic criteria /U. Nussinovitch// Arch Immunol Ther Exp-2009.-vol. 57.-p. 95−104.
- Jahns R, Boivin V, Hein L et al. Direct evidence for a betal-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy /R. Jahns // J Clin Invest-2004.-vol. 113.-p. 1419−1429.
- Chiale PA, Garro PIA, Schmidberg J et al. Inappropriate sinus tachycardia may be related to an immunologic disorder in volving cardiac et a adrenergic receptors /PA Chiale// Heart Rhythm -2006.-vol. 3.-p. 1182−1186.
- Magnusson Y, Marullo S, Ployer S et al. Mapping of a functional autoimmune epitope on the beta 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy /Y. Magnusson// J Clin Invest -1990.-vol. 86.-p. 1658−1663.
- Liu I-IR, Zhao RR, Zhi JM et al. Screening of serum autoantibodies to cardiac betal-adrenoceptors and M2-muscarinic acetylcholine receptors in 408 healthy subjects of varying ages /PIR Liu// Autoimmunity-1999.-vol. 29.-p. 43−51.
- Jahns R, Boivin V, Siegmund C et al. Activating beta-1-adrenoceptor antibodies are not associated with cardiomyopathies secondary to valvular or hypertensive heart disease /R. Jahns// J Am Coll Cardio- 1999.-vol. 1 34.-p. 1545−1551.
- Jahns R, Boivin V, Siegmund C, et al. Autoantibodies activating human hl-adrenergicreceptors are associated with reduced cardiac function in chronic heart failure /R. Jahns// Circulation-1999-.- vol. 99, — p. 649−654.
- Limas CJ, Goldenberg IF, Limas C. Assessment of immune modulation of had renergic pathways in human dilated cardiomyopathy: influence of methodologic factors /CJ Limas// Am Heart J-1992.-vol. 123.-p. 967−970.
- Magnusson Y, Wallukat G, Waagstein F et al. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the? l-adrenoceptor with positive chronotropic effect /Y. Magnusson// Circulation-1994,-vol. 89.-p. 2760−2767.
- Matsumori A, Ono K, Nishio R et al. Amiodarone inhibits production of tumor necrosis factor-a by human mononuclear cells: a possible mechanism for its effect in heart failure /A. Matsumori// Circulation- 1997.-vol. 96.-p. 1386— 1389.
- Matsumori A. Molecular and immune mechanisms in the pathogenesis of cardiomyopathy: role of viruses, cytokines, and nitric oxide /A. Matsumori// JpnCirc J-1997.- vol. 61.-p. 275−291.
- Packer M, O’Connor CM, Ghali JK et al., for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure /M. Packer// N Engl J Med -1996.-vol. 335.-p. 1107−1114.
- Godsel LM, Leon JS, Engman DM. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in experimental myocarditis /LM Godsel// Curr Pharm Des-2003.-vol. 9(9).-p. 723−35.
- Bahk TJ, Daniels MD, Leon JS et al. Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis /TJ Bahk// Int J Cardiol-2008.-vol. 125(l).-p. 85−93.
- Daniels MD, Hyland KV, Engman DM. Treatment of experimental myocarditis via modulation of the renin-angiotensin system /MD Daniels// Curr Pharm Des-2007.-vol. 13(13).-p. 1299−1305.
- Yokoseki O, Suzuki J, Kitabayashi H et al. Cis element decoy against nuclear factor-kappa B attenuates development of experimental autoimmune myocarditis in rats /0. Yokoseki// Circ Res- 2001.-vol. 89.-p. 899−906.
- Kwon HJ, Cote TR, Cuffe MS. Case report of heart failure after therapy with a tumor necrosis factor antagonist /HJ Kwon// Ann Intern Med-2003.-vol. 138.-p. 807−811.
- Isic A, Scharin Tang M, Haugen E, Fu M. TNF alpha-antagonist neither improve cardiac remodelling or cardiac function at early stage of heart failure in diabetic rats /A. Isic// Autoimmunity-2008.-vol. 41(6).-p. 473−477.
- Matsumori A, Wang H, Abelmann WH, Crumpacker CS. Treatment of viral myocarditis with ribavirin in an animal preparation /A. Matsumori// Circulation-1985.-vol. 71.-p. 834−839.
- Matsumori A, Crumpacker CS, Abelmann WH. Prevention of viral myocarditis with recombinant human leukocyte interferon a A/D in a murine model /A. Matsumori//J Am Coll Cardiol-1987.-vol. 9.-p. 1320−1325.
- ITuber SA, Job LP, Woodruff JF. Lysis of infected myofibers by coxsackievirus B-3-immune T lymphocytes /SA Huber//Am J Pathol- 1980.-vol. 98.-p. 681−694.
- Drucker NA, Colan SD, Lewis AB et al. y-Globulin treatment of acute myocarditis in the pediatric population /NA Drucker// Circulation-1994.- vol. 89.-p. 252−257.
- Newburger JW, Sanders SP, Burns JC et al. Left ventricular contractility and functions in Kawasaki syndrome: effect of intravenous gamma globulin /JW Newburger//Circulation-1989.-vol. 79.-p. 1237−1246.
- Matsumori A, Yamada T, Kawai C. Immunomodulating therapy in viral myocarditis: effects of tumor necrosis factor, interleukin 2 and anti-interleukin-2 receptor antibody in an animal model /Π. Matsumori// Eur Heart J-1991.-vol. 12.-p. 203−205.
- Du Bois JS, Udelson JE, Atkins MB. Severe reversible global and regional ventricular dysfunction associated with high-dose interleukin-2 immunotherapy /JS Du Bois// J Immunother-1995.-vol. 18.-p.l 19−123.
- Tomioka N, Kishimoto C, Matsumori A, Kawai C. Effects of prednisolone on acute viral myocarditis in mice /N. Tomioka// J Am Coll Cardiol-1986.-vol. 7.-p. 868−872.
- Kishimoto C, Abelmann WH. Absence of effects of cyclosporine on myocardial lymphocyte subsets in coxsackievirus B3 myocarditis in the aviremic stage /Π‘. Kishimoto// Circ Res-1989.-vol. 65.-p. 934−945.
- Hiraoka Y, Kishimoto C, Kurokawa M et al. The effects of FK-506, a novel and potent immunosuppressant, upon murine coxsackievirus B3 myocarditis /Y. Hiraoka// J Pharma col Exp Ther- 1991.-vol. 260.-p. 13 861 391.
- Kishimoto C, Thorp KA, Abelmann WH. Immunosuppression with high doses of cyclophosphamide reduces the severity of myocarditis but increases the mortality in murine coxsackievirus B3 myocarditis / C. Kishimoto//Circulation-1990.-vol. 82.-p. 982−989.
- M. Π. Π‘ΠΈΠ΄ΠΎΡΠΎΠ²Π°, M. E. ΠΠ°Π»ΡΠΊΠ΅Π΅Π²Π°, Π. Π‘. ΠΠΎΠ»ΠΎΠΊΠΎΠ΅Π΄ΠΎΠ² ΠΈ Π΄Ρ. Π‘ΠΈΠ½ΡΠ΅Π· ΠΈ ΡΠ²ΠΎΠΉΡΡΠ²Π° Π½ΠΎΠ²ΠΎΠ³ΠΎ ΠΊΠΎΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ Π°Π½ΡΠΈΠ³Π΅Π½Π°, ΠΌΠΎΠ΄Π΅Π»ΠΈΡΡΡΡΠ΅Π³ΠΎΠ²Π½Π΅ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ ΡΠ°ΡΡΡ (31-Π°Π΄ΡΠ΅Π½ΠΎΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° /Π. Π. Π‘ΠΈΠ΄ΠΎΡΠΎΠ²Π°// ΠΠΈΠΎΠΎΡΠ³. Ρ ΠΈΠΌΠΈΡ-2009.-№ 35(3).-Ρ. 311−322.
- Shishehbor ΠΠ, Alves Π‘, Rajagopal V. Inflammation: implications for understanding the heart-brain connection /ΠΠ Shishehbor// Cleve Clin J Med-2007.-vol. 74.-p. S37−41.
- Sabeti M, Kermani V, Sabeti S, Simon JH. Significance of human Cytomegalovirus and Epstein-Barr Virus in inducing cytokine expression in periapical lesions /Π. Sabeti//J Endod-2012.-vol. 38(l).-p. 47−50.
- Huen DS, Fox A, Kumar P, Searle PF. Dilated heart failure in transgenic mice expressing the Epstein-Barr virus nuclear antigen-leader protein /DS Pluen//J Gen Virol-1993.- vol. 74.-p. 1381−1391.
- Adamsson Eryd S, Smith JG, Melander Π et al. Inflammation-sensitive proteins and risk of atrial fibrillation: a population-based cohort study /Adamsson Eryd S// Eur J Epidemiol-2011 .-vol. 26(6)-p. 449−55.
- Dernellis J, Panaretou M. Effects of C-reactive protein and the third and fourth components of complement (C3 and C4) on incidence of atrial fibrillation/J. Dernellis// Am J Cardiol-2006.- vol. 97(2).-p. 245−248.
- Abdalla IS, Prineas RJ, Neaton JD et al. Relation between ventricular premature complexes and sudden cardiac death in apparently healthy men /IS Abdalla// Am J Cardiol- 1987.-vol. 60.-p. 1036−1042.
- Fleg JL, Kennedy HL. Cardiac arrhythmias in a healthy elderly population detected by 24-hour ambulatory electrocardiography /JL Fleg// Chest-1982.- vol. 81.-p. 302−307.
- Kennedy PIL, Whitlock JA, Sprague MK et al. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy /PIL Kennedy//N Engl JMed-1985.-vol. 312.-p. 193−197.
- Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells /SN Waggoner// Nature- 2011 .-vol. 481.-p. 394−398.
- Higa C, Ciambrone G, Donato MS et al. NT-Pro-BNP levels performance before and after reversion to sinus rhythm in patients with preserved ventricular function /C. Higa// Medicina (B Aires)-201 l.-vol. 71(2).-p. 146−50.
- Sajadieh A, Nielsen OW, Rasmussen V et al. Prevalence and prognostic significance of daily-life silent myocardial ischemiain middle-aged and elderly subjects with no apparent heart disease /A. Sajadieh// Eur Heart J-2005.-vol. 26-p. 1402−1409.
- Wang WZ, Zhao RR, Wu BW et al. Effects of anti-peptide antibodies against human M2 muscarinic receptors on cardiac function in rats in vivo /WZ Wang//Blood Press Suppl-1996.-vol.3.-p. 25−27.